Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Jun 29, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Jun 29, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Jun 29, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | May 14, 1996 | openfda |
| Dordaviprone | US FDA | Diffuse Midline Glioma | MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. ( 1 ) This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated | approved | Aug 6, 2025 | openfda |
| Dostarlimab | US FDA | Tumor-agnostic | as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. • Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 1 • 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated | approved | Apr 22, 2021 | openfda |
| Dostarlimab | US FDA | Malignant Endometrial Neoplasm | Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). | approved | Apr 22, 2021 | openfda |
| Doxorubicin | US FDA | Multiple Myeloma | Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy | approved | Nov 17, 1995 | openfda |
| Doxorubicin | US FDA | Malignant Ovarian Neoplasm | Ovarian cancer: After failure of platinum-based chemotherapy | approved | Nov 17, 1995 | openfda |
| Doxorubicin | US FDA | AIDS-Related Kaposi Sarcoma | AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy | approved | Nov 17, 1995 | openfda |
| Doxorubicin | US FDA | Malignant Breast Neoplasm | as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer | approved | Dec 23, 1987 | openfda |
| Durvalumab | US FDA | Lung Small Cell Carcinoma | in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Lung Non-Small Cell Carcinoma | as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Lung Non-Small Cell Carcinoma | in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Lung Small Cell Carcinoma | as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Malignant Biliary Tract Neoplasm | in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Malignant Bladder Neoplasm | in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Gastroesophageal Junction Adenocarcinoma | in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Malignant Endometrial Neoplasm | in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Hepatocellular Carcinoma | in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). | approved | May 1, 2017 | openfda |
| Durvalumab | US FDA | Non-Muscle Invasive Bladder Carcinoma | in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). | approved | May 1, 2017 | openfda |
| Elacestrant | US FDA | Malignant Breast Neoplasm | ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] , with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 ) | approved | Jan 27, 2023 | openfda |
| Elotuzumab | US FDA | Multiple Myeloma | EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. | approved | Nov 30, 2015 | openfda |
| Elotuzumab | US FDA | Multiple Myeloma | EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in | approved | Nov 30, 2015 | openfda |
| Elotuzumab | US FDA | Multiple Myeloma | combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. (1) | approved | Nov 30, 2015 | openfda |
| Elotuzumab | US FDA | Multiple Myeloma | combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (1) | approved | Nov 30, 2015 | openfda |
| Elranatamab | US FDA | Multiple Myeloma | ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )accelerated | approved | Aug 14, 2023 | openfda |
| Enasidenib | US FDA | Acute Myeloid Leukemia | IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test | approved | Aug 1, 2017 | openfda |
| Encorafenib | US FDA | Lung Non-Small Cell Carcinoma | Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test. | approved | Jun 27, 2018 | openfda |
| Encorafenib | US FDA | Malignant Colorectal Neoplasm | Colorectal Cancer (CRC) • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorized test. | approved | Jun 27, 2018 | openfda |
| Encorafenib | US FDA | Melanoma | Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. | approved | Jun 27, 2018 | openfda |
Data updated 18 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 403 | 92 | 310 |
| Dasatinib | 313 | 179 | 134 |
| Imatinib | 274 | 144 | 130 |
| Erlotinib | 268 | 174 | 94 |
| Crizotinib | 262 | 141 | 121 |
| Vemurafenib | 261 | 149 | 111 |
| Gefitinib | 185 | 142 | 43 |
| Sunitinib | 164 | 91 | 72 |
| Trametinib | 157 | 129 | 28 |
| Afatinib | 129 | 120 | 9 |
| Panitumumab | 127 | 34 | 93 |
| Trastuzumab | 127 | 90 | 37 |
| Olaparib | 108 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 105 |
| 3 |
| Dabrafenib | 107 | 74 | 33 |
| Imatinib Mesylate | 100 | 20 | 80 |
| Sorafenib | 95 | 72 | 23 |
| Bosutinib | 91 | 32 | 59 |
| Lapatinib | 85 | 64 | 21 |
| Selumetinib | 85 | 71 | 14 |
| Palbociclib | 84 | 75 | 9 |
| Larotrectinib | 79 | 63 | 16 |
| Cisplatin | 77 | 45 | 31 |
| Entrectinib | 69 | 62 | 7 |
| Ponatinib | 67 | 56 | 11 |
| Nilotinib | 65 | 20 | 45 |
| Osimertinib | 62 | 48 | 14 |
| Chemotherapy | 61 | 39 | 22 |
| Axitinib | 57 | 17 | 40 |
| Erdafitinib | 54 | 51 | 3 |
| Dactolisib | 53 | 44 | 9 |
| Pembrolizumab | 53 | 38 | 12 |
| Bevacizumab | 45 | 33 | 12 |
| Irinotecan | 44 | 12 | 32 |
| Fluorouracil | 43 | 28 | 12 |
| Gemcitabine | 43 | 29 | 13 |
| Neratinib | 43 | 40 | 3 |
| Regorafenib Anhydrous | 43 | 24 | 19 |
| Selpercatinib | 43 | 34 | 9 |
| Doxorubicin | 41 | 9 | 32 |
| Alectinib | 40 | 18 | 22 |
| Ceritinib | 40 | 27 | 13 |
| Everolimus | 39 | 34 | 4 |
| Carboplatin | 38 | 29 | 9 |
| Venetoclax | 37 | 4 | 33 |
| Fulvestrant | 35 | 30 | 5 |
| Paclitaxel | 35 | 21 | 13 |
| Vismodegib | 35 | 9 | 26 |
| Midostaurin | 33 | 28 | 4 |
| Futibatinib | 32 | 29 | 3 |
| Mercaptopurine | 31 | 2 | 28 |
| Rucaparib | 31 | 31 | 0 |
| Infigratinib | 30 | 26 | 4 |
| Sirolimus | 30 | 25 | 5 |
| Docetaxel | 29 | 20 | 9 |
| Nivolumab | 29 | 20 | 6 |
| Thioguanine | 29 | 0 | 28 |
| Lorlatinib | 28 | 21 | 7 |
| Atezolizumab | 26 | 21 | 3 |
| Pazopanib | 26 | 25 | 1 |
| Pictilisib | 26 | 25 | 1 |
| Melphalan | 25 | 1 | 24 |
| Binimetinib | 24 | 23 | 1 |
| Pertuzumab | 24 | 24 | 0 |
| Tazemetostat | 24 | 24 | 0 |
| Trastuzumab Deruxtecan | 24 | 24 | 0 |
| MDM2 Inhibitor AMGMDS3 | 23 | 1 | 22 |
| Talazoparib | 23 | 23 | 0 |
| Temozolomide | 23 | 20 | 3 |
| Capivasertib | 22 | 21 | 1 |
| Crenolanib | 22 | 21 | 1 |
| Oxaliplatin | 22 | 6 | 16 |
| Quizartinib | 22 | 13 | 8 |
| BRAF Inhibitor | 21 | 21 | 0 |
| Brigatinib | 21 | 12 | 9 |
| Gilteritinib | 21 | 18 | 3 |
| Alpelisib | 20 | 15 | 5 |
| Cobimetinib | 20 | 20 | 0 |
| Enzalutamide | 20 | 8 | 12 |
| Aspirin | 19 | 19 | 0 |
| Regorafenib | 19 | 12 | 7 |
| Tamoxifen | 19 | 11 | 8 |
| Trastuzumab Emtansine | 19 | 10 | 9 |
| Cabozantinib | 18 | 17 | 1 |
| Capecitabine | 18 | 11 | 4 |
| Capmatinib | 18 | 15 | 1 |
| Sotorasib | 18 | 17 | 0 |
| Cytarabine | 17 | 5 | 12 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 17 | 15 | 2 |
| Pralsetinib | 17 | 11 | 6 |
| Dacomitinib | 16 | 15 | 1 |
| Immune Checkpoint Inhibitor | 16 | 13 | 2 |
| Ivosidenib | 16 | 16 | 0 |
| Lestaurtinib | 16 | 15 | 1 |
| Pemetrexed | 16 | 11 | 5 |
| PI103 | 16 | 16 | 0 |
| Temsirolimus | 16 | 15 | 1 |
| ALK Inhibitor TAE684 | 15 | 12 | 3 |
| Daunorubicin | 15 | 4 | 11 |
| Tepotinib | 15 | 15 | 0 |
| Abiraterone | 14 | 3 | 11 |
| Encorafenib | 14 | 13 | 1 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 14 | 10 | 4 |
| Methotrexate | 14 | 2 | 9 |
| Pexidartinib | 14 | 6 | 8 |
| Platinum Compound | 14 | 13 | 1 |
| Tretinoin | 14 | 8 | 6 |
| Bafetinib | 13 | 1 | 12 |
| Dovitinib | 13 | 13 | 0 |
| Ruxolitinib | 13 | 13 | 0 |
| Ibrutinib | 12 | 6 | 6 |
| Prednisone | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Durvalumab | 11 | 10 | 1 |
| Mirdametinib | 11 | 9 | 2 |
| PD173074 | 11 | 10 | 1 |
| Revumenib | 11 | 4 | 7 |
| Akt Inhibitor MK2206 | 10 | 9 | 1 |
| Asparaginase | 10 | 0 | 10 |
| Etoposide | 10 | 7 | 3 |
| Fexagratinib | 10 | 9 | 1 |
| PLX4720 | 10 | 5 | 4 |
| R3Mab | 10 | 5 | 5 |
| JQ1 | 9 | 9 | 0 |
| PI3Ka/Di | 9 | 7 | 2 |
| Vandetanib | 9 | 8 | 1 |
| Inavolisib | 8 | 8 | 0 |
| Ipilimumab | 8 | 6 | 1 |
| MEK Inhibitor CI-1040 | 8 | 8 | 0 |
| Niraparib | 8 | 8 | 0 |
| Panobinostat | 8 | 7 | 1 |
| Ribociclib | 8 | 5 | 3 |
| Vorinostat | 8 | 7 | 1 |
| Azacitidine | 7 | 7 | 0 |
| Foretinib | 7 | 6 | 1 |
| GSK126 | 7 | 7 | 0 |
| Mitomycin | 7 | 6 | 1 |
| MTOR Inhibitor | 7 | 7 | 0 |
| Multikinase Inhibitor AEE788 | 7 | 5 | 2 |
| Pemigatinib | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Repotrectinib | 7 | 7 | 0 |
| Sonidegib | 7 | 4 | 3 |
| Sunvozertinib | 7 | 7 | 0 |
| Taselisib | 7 | 6 | 1 |
| VTP-50469 | 7 | 0 | 7 |
| Arsenic Trioxide | 6 | 3 | 3 |
| AZD3463 | 6 | 1 | 5 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Dinaciclib | 6 | 5 | 1 |
| Ipilimumab/Nivolumab Regimen | 6 | 6 | 0 |
| Linsitinib | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 6 | 6 | 0 |
| Radiation Therapy | 6 | 4 | 2 |
| Sapanisertib | 6 | 6 | 0 |
| Tanespimycin | 6 | 6 | 0 |
| Trabectedin | 6 | 6 | 0 |
| Veliparib | 6 | 6 | 0 |
| Adavosertib | 5 | 5 | 0 |
| ALK Inhibitor ASP3026 | 5 | 1 | 4 |
| Amivantamab | 5 | 5 | 0 |
| Buparlisib | 5 | 5 | 0 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| MEK Inhibitor RO4987655 | 5 | 1 | 4 |
| Metformin | 5 | 5 | 0 |
| MTOR Kinase Inhibitor PP242 | 5 | 4 | 1 |
| PD1 Inhibitor | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Adagrasib | 4 | 4 | 0 |
| Anti-PD1 Monoclonal Antibody | 4 | 3 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 4 | 2 | 2 |
| Apitolisib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| ARS-1620 | 4 | 3 | 0 |
| Asciminib | 4 | 4 | 0 |
| Bicalutamide | 4 | 1 | 3 |
| Decitabine | 4 | 4 | 0 |
| Dordaviprone | 4 | 4 | 0 |
| Duligotuzumab | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| Eprenetapopt | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| JQEZ5 | 4 | 4 | 0 |
| Lenvatinib | 4 | 3 | 1 |
| Letrozole | 4 | 3 | 1 |
| Leucovorin | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 4 | 2 | 2 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 4 | 4 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 4 | 4 | 0 |
| PI3K/BET Inhibitor LY294002 | 4 | 4 | 0 |
| Poziotinib | 4 | 4 | 0 |
| Refametinib | 4 | 3 | 1 |
| Rogaratinib | 4 | 4 | 0 |
| Taxane Compound | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vincristine | 4 | 3 | 1 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| Abiraterone Acetate | 3 | 0 | 3 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ATR Inhibitor | 3 | 3 | 0 |
| Avapritinib | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Birabresib | 3 | 3 | 0 |
| Bortezomib | 3 | 3 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 3 | 3 | 0 |
| Cabazitaxel | 3 | 2 | 1 |
| Canertinib | 3 | 3 | 0 |
| CDK Inhibitor SNS-032 | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dostarlimab | 3 | 3 | 0 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| IGF1R Monoclonal Antibody | 3 | 3 | 0 |
| Immunotherapy | 3 | 3 | 0 |
| Ipatasertib | 3 | 3 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Mobocertinib | 3 | 3 | 0 |
| PD98059 | 3 | 1 | 2 |
| Perifosine | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| RapaLink-1 | 3 | 1 | 2 |
| RDEA 119 | 3 | 3 | 0 |
| RG7112 | 3 | 2 | 1 |
| Ridaforolimus | 3 | 2 | 1 |
| Savolitinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tandutinib | 3 | 2 | 1 |
| Tegafur | 3 | 0 | 0 |
| Teprotumumab | 3 | 3 | 0 |
| Tipifarnib | 3 | 3 | 0 |
| Trastuzumab Deruxtecan | 3 | 3 | 0 |
| Tremelimumab | 3 | 3 | 0 |
| Trichostatin A | 3 | 2 | 1 |
| Zongertinib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Alvocidib | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Angiogenesis Inhibitor | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Belinostat | 2 | 0 | 0 |
| BET Inhibitor | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| CDK4/6 Inhibition | 2 | 1 | 1 |
| Cediranib | 2 | 2 | 0 |
| Celecoxib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Chk1 Inhibitor | 2 | 2 | 0 |
| Copanlisib | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Elimusertib | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ganetespib | 2 | 1 | 1 |
| Ganitumab | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Izorlisib | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Meloxicam | 2 | 2 | 0 |
| Mocetinostat | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Navtemadlin | 2 | 2 | 0 |
| Nimotuzumab | 2 | 2 | 0 |
| Nirogacestat | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| Pidnarulex | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Rebemadlin | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rezatapopt | 2 | 2 | 0 |
| RG7356 | 2 | 1 | 1 |
| Rigosertib | 2 | 0 | 2 |
| Ripretinib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| SAIT301 | 2 | 2 | 0 |
| Salinomycin | 2 | 2 | 0 |
| Salirasib | 2 | 2 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Selitrectinib | 2 | 2 | 0 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tarextumab | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Tovorafenib | 2 | 2 | 0 |
| Triciribine | 2 | 2 | 0 |
| Tucatinib | 2 | 2 | 0 |
| Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Vatalanib | 2 | 2 | 0 |
| Verteporfin | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| ACLY SiRNA | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Afamitresgene Autoleucel | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| Agerafenib | 1 | 1 | 0 |
| AKTi-1/2 | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK/TRK Inhibitor TSR-011 | 1 | 0 | 1 |
| AMG511 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Anvumetostat | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| ARQ092 | 1 | 1 | 0 |
| ARS-853 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD5438 | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAN508 | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carfilzomib | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Chlorambucil | 1 | 1 | 0 |
| Chloroquine | 1 | 1 | 0 |
| CHMFL-KIT-031 | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Cytoreductive Surgery | 1 | 1 | 0 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EFTX-G12V | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Enfortumab Vedotin | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FACT Complex-targeting Curaxin CBL0137 | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FEC Regimen | 1 | 0 | 1 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGFR Inhibitor ASP5878 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| G-573 | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| GDC-0879 | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| GNE-617 | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDAC Inhibitor REC-2282 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HER2 Inhibitor CP-724,714 | 1 | 0 | 1 |
| Hydroxychloroquine | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| Hyperthermic Intraperitoneal Chemotherapy | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Inhibitor | 1 | 1 | 0 |
| Iniparib | 1 | 1 | 0 |
| Interventional Radiology Procedure | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| KG5 | 1 | 0 | 1 |
| KU-0060648 | 1 | 1 | 0 |
| Larotrectinib Regimen | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Leuprolide | 1 | 1 | 0 |
| Lifirafenib | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor GDC-0623 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Niacinamide | 1 | 0 | 1 |
| Nilutamide | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| NU7441 | 1 | 1 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Pan-RAF Inhibitor LY3009120 | 1 | 1 | 0 |
| PARP Inhibitor ABT-888 | 1 | 1 | 0 |
| PARP Inhibitor AZD2461 | 1 | 1 | 0 |
| Pasireotide | 1 | 1 | 0 |
| Patidegib | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-180970 | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pegargiminase | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| RG5 | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Seribantumab | 1 | 1 | 0 |
| Sertraline | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Sorafenib Tosylate | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| TRK Inhibitor | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| VEGF/VEGFR Inhibitors | 1 | 1 | 0 |
| Vociprotafib | 1 | 0 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
| WZ4002 | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.